151
Participants
Start Date
October 31, 2004
Primary Completion Date
November 30, 2007
Study Completion Date
November 30, 2007
bosutinib
Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
bosutinib
400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
bosutinib
400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
bosutinib
400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
Pfizer Investigational Site, New York
Pfizer Investigational Site, New York
Pfizer Investigational Site, Baltimore
Pfizer Investigational Site, UNC Chapel Hill
Pfizer Investigational Site, UNC Chapel Hill
Pfizer Investigational Site, Charlotte
Pfizer Investigational Site, Charlotte
Pfizer Investigational Site, Atlanta
Pfizer Investigational Site, Tampa
Pfizer Investigational Site, Birmington
Pfizer Investigational Site, Indianpolis
Pfizer Investigational Site, Detroit
Pfizer Investigational Site, Lansing
Pfizer Investigational Site, Tyler
Pfizer Investigational Site, San Antonio
Pfizer Investigational Site, Scottsdale
Pfizer Investigational Site, Los Angeles
Pfizer Investigational Site, Seattle
Pfizer Investigational Site, Cleveland
Lead Sponsor
Pfizer
INDUSTRY